Perspective Therapeutics Inc
For the period ended Mar 31, 2024. Filed May 15, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2024 · Filed May 15, 2024
CATX$0.86+1.9%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 6. Exhibits
(Except as otherwise indicated (a) all exhibits were previously filed, (b) all omitted exhibits are intentionally omitted, and (c) all documents referenced below were filed under SEC file number 001-33407.)
| Exhibits: | |
|---|---|
| 2.1 | Agreement and Plan of Merger, dated September 27, 2022, by and between Isoray, Inc., Isoray Acquisition Corp., Viewpoint Molecular Targeting, Inc., and Cameron Gray, incorporated by reference to Exhibit 2.1 of the Form 8-K filed on September 28, 2022. |
| 2.2 | First Amendment to Agreement and Plan of Merger, dated October 21, 2022, between Isoray, Inc., Isoray Acquisition Corp., Viewpoint Molecular Targeting, Inc., and Cameron Gray, incorporated by reference to Exhibit 2.1 of the Form 8-K filed on October 24, 2022. |
| 2.3 | Amendment No. 1 to Asset Purchase Agreement, dated March 28, 2024, by and among Isoray Medical, Inc., GT Medical Technologies, Inc., and Perspective Therapeutics, Inc., incorporated by reference to Exhibit 2.1 of the Form 8-K filed on April 3, 2024. |
| 3(i) | Amended and Restated Certificate of Incorporation of Perspective Therapeutics, Inc. as of February 14, 2023, incorporated by reference to Exhibit 3.1 of the Form 8-K filed on February 16, 2023. |
| 3(ii) | Amended and Restated Bylaws of Perspective Therapeutics, Inc. as of February 14, 2023, incorporated by reference to Exhibit 3.2 of the Form 8-K filed on February 16, 2023. |
| 4 | Form of Pre-funded Warrant to Purchase Common Stock, incorporated by reference to Exhibit 4.1 of the Form 8-K filed on January 22, 2024. |
| 10.1#+ | Investment Agreement, dated January 8, 2024, by and between Perspective Therapeutics, Inc. and Lantheus Alpha Therapy, LLC, incorporated by reference to Exhibit 10.1 of the Form 8-K/A filed on January 17, 2024. |
| 10.2+ | Investment Agreement, dated March 4, 2024, by and among Perspective Therapeutics, Inc. and the parties identified on Schedule 1 thereto, incorporated by reference to Exhibit 10.1 of the Form 8-K filed on March 6, 2024. |
| 10.3 | Registration Rights Agreement, dated January 22, 2024, by and between the Company and Lantheus Alpha Therapy, LLC, incorporated by reference to Exhibit 10.26 of the Form 10-K filed on March 28, 2024. |
| 10.4#+ | Option Agreement, dated January 8, 2024, by and between Perspective Therapeutics, Inc. and Lantheus Alpha Therapy, LLC, incorporated by reference to Exhibit 10.3 of the Form 8-K/A filed on January 17, 2024. |
| 10.5# | Asset Purchase Agreement, dated January 8, 2024, by and between Perspective Therapeutics, Inc. and Progenics Pharmaceuticals, Inc., incorporated by reference to Exhibit 10.2 of the Form 8-K/A filed on January 17, 2024. |
| 10.6+ | Placement Agency Agreement, dated March 4, 2024, by and between Perspective Therapeutics, Inc. and Oppenheimer & Co. Inc., incorporated by reference to Exhibit 10.2 of the Form 8-K filed on March 6, 2024. |
| 10.7 | Registration Rights Agreement, dated March 6, 2024, by and among Perspective Therapeutics, Inc. and each of the purchasers identified on Schedule 1 thereto, incorporated by reference to Exhibit 10.3 of the Form 8-K filed on March 6, 2024. |
| 31.1* | Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. |
| 31.2* | Certification of Co-Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. |
| 31.3* | Certification of Co-Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. |
| 32** | Certification of Principal Executive Officer and Co-Principal Financial Officers Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. |
| 101.INS* | Inline XBRL Instance Document |
| 101.SCH* | Inline XBRL Taxonomy Extension Schema with Embedded Linkbase Documents |
| 104 | Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101) |
- Filed herewith
** Furnished herewith
Certain portions of this exhibit (indicated by asterisks) have been omitted pursuant to Item 601(b)(10)(iv) of Regulation S-K.
- Certain schedules and exhibits have been omitted pursuant to Item 601(a)(5) of Regulation S-K. The Company will furnish supplementally a copy of any omitted schedule or exhibit to the Securities and Exchange Commission upon request. The Company may request confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended, for any schedules or exhibits so furnished.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.